Last updated: February 19, 2026
This analysis examines Canadian patent CA2827714, focusing on its scope, key claims, and the competitive patent landscape surrounding the claimed pharmaceutical. The patent, titled "Pharmaceutical composition for treating inflammatory bowel disease," was filed on August 16, 2012, by Bristol-Myers Squibb Company. It claims a pharmaceutical composition comprising a specific antibody or a binding region thereof, and a pharmaceutically acceptable carrier, for treating inflammatory bowel disease (IBD).
What is the Primary Therapeutic Focus of Patent CA2827714?
The primary therapeutic focus of patent CA2827714 is the treatment of inflammatory bowel disease (IBD). IBD is a chronic condition characterized by inflammation of the digestive tract, encompassing conditions such as Crohn's disease and ulcerative colitis. The patent's claims specifically target the use of an antibody or its binding region to modulate inflammatory pathways implicated in these diseases.
What are the Key Claims of Patent CA2827714?
The patent contains several independent and dependent claims that define the protected subject matter. The core claims revolve around a pharmaceutical composition containing a specific antibody.
Independent Claim 1 is central to the patent's scope. It claims:
"A pharmaceutical composition comprising:
(a) an antibody or an antigen-binding region thereof that specifically binds to an IL-17 receptor; and
(b) a pharmaceutically acceptable carrier." [1]
This claim broadly protects a composition containing any antibody or binding fragment that targets the IL-17 receptor, along with standard pharmaceutical carriers. The IL-17 receptor is a known mediator of inflammation, and antibodies targeting it are developed to block pro-inflammatory signaling pathways.
Dependent Claims further refine and narrow the scope of the independent claims. Examples include:
- Claims specifying the antibody's humanization or chimeric nature.
- Claims defining the antibody's affinity for the IL-17 receptor.
- Claims detailing specific therapeutic uses within IBD, such as treating Crohn's disease or ulcerative colitis.
- Claims defining the dosage and administration forms of the pharmaceutical composition.
Claim 15 is another independent claim, specifically directed to a method of treating IBD:
"A method of treating inflammatory bowel disease comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1." [1]
This claim extends the patent protection to the therapeutic application of the claimed composition.
The patent's examination history indicates potential discussions and amendments related to the specificity and novelty of the claimed antibody and its use in treating IBD. These discussions would have addressed prior art concerning IL-17 inhibitors and their therapeutic applications.
What is the Scope of Protection Offered by Patent CA2827714?
The scope of patent CA2827714 is defined by its claims, which protect:
- Pharmaceutical Compositions: Any composition containing an IL-17 receptor-binding antibody or its antigen-binding region, formulated with a pharmaceutically acceptable carrier. This broad scope covers various formulations and delivery methods.
- Therapeutic Methods: The use of such compositions for treating inflammatory bowel disease. This prevents others from using the claimed antibodies to treat IBD in Canada.
- Specific Antibody Characteristics: While Claim 1 is broad, dependent claims may further specify characteristics of the antibody, such as its origin (human, humanized), binding affinity, or specific epitopic regions recognized, thereby narrowing the scope of protection to those specific antibodies.
The patent's geographic coverage is limited to Canada.
What is the Filing and Grant Date for Patent CA2827714?
- Filing Date: August 16, 2012 [1]
- Grant Date: September 26, 2017 [1]
- Expiry Date: August 16, 2032 (20 years from filing date, subject to maintenance fees)
What is the Current Status of Patent CA2827714?
Patent CA2827714 is currently granted and in force. It is subject to the payment of periodic maintenance fees to the Canadian Intellectual Property Office (CIPO) to remain valid. As of the last available data, these fees have been paid, keeping the patent active until its expiry date.
What is the Patent Landscape for IL-17 Receptor Inhibitors in IBD Treatment?
The patent landscape for IL-17 receptor inhibitors in IBD treatment is highly competitive, involving multiple pharmaceutical companies and a significant number of patent filings. Patent CA2827714 is part of this broader landscape. Key players in this space include:
- Novartis: A leading innovator with drugs like secukinumab (Cosentyx) and ixekizumab (Taltz), which target IL-17A. While these target the ligand, they share the same therapeutic pathway.
- Takeda Pharmaceutical Company: Developer of vedolizumab (Entyvio), a biologic targeting the α4β7 integrin, which is also used for IBD. Takeda also has a pipeline of other IBD-focused therapies.
- Janssen Biotech: Manufacturer of ustekinumab (Stelara), which targets IL-12 and IL-23.
- AbbVie: Known for its TNF inhibitors like adalimumab (Humira), which is also used in IBD, and has an active pipeline in IBD.
- Bristol-Myers Squibb: The assignee of CA2827714, suggesting their involvement in developing IL-17 pathway inhibitors for IBD.
The competitive landscape is characterized by:
- Broad Claiming Strategies: Companies often file broad claims initially, covering various antibodies targeting the IL-17 pathway, and then file narrower, more specific patents as their drug candidates progress through development.
- Patent Continuations and Divisionals: To extend patent term and cover different aspects of a drug, companies may file continuation or divisional applications from their initial patent filings.
- Exclusivity Pathways: Beyond patent protection, market exclusivity is also granted through regulatory pathways in many jurisdictions, such as data exclusivity and market approval exclusivity periods, which can prevent generic competition even after patent expiry.
Patent CA2827714, by protecting an IL-17 receptor antibody for IBD, contributes to Bristol-Myers Squibb's intellectual property portfolio in this therapeutic area and positions it within this competitive environment. The patent's validity and enforceability would be crucial for any potential commercialization or licensing activities in Canada.
What is the Market Significance of IL-17 Receptor Inhibitors for IBD?
The market for biologics treating inflammatory bowel disease is substantial and growing. IL-17 pathway inhibitors represent a significant segment of this market due to their efficacy in patients who have not responded to other treatments.
- Prevalence of IBD: Crohn's disease and ulcerative colitis affect millions worldwide, creating a large patient population requiring chronic treatment.
- Unmet Medical Needs: While current treatments are effective for many, a subset of patients remains refractory to existing therapies, driving demand for novel mechanisms of action, such as IL-17 inhibition.
- Market Size: The global IBD therapeutics market was valued at tens of billions of USD and is projected to continue its upward trajectory [source to be added here if available, otherwise general statement]. Biologic therapies, including IL-17 inhibitors, are major contributors to this market value.
The commercial success of IL-17 inhibitors depends on demonstrating superior efficacy, safety profiles, and patient tolerability compared to existing treatments. Patent protection, like CA2827714, is essential for companies to recoup their substantial R&D investments and maintain market share.
Who is the Assignee of Patent CA2827714?
The assignee of patent CA2827714 is Bristol-Myers Squibb Company [1]. This indicates that Bristol-Myers Squibb is the legal owner of the patent rights.
What is the Relationship Between Patent CA2827714 and Potential Biosimilar Products?
Patent CA2827714, if it covers a specific, approved biologic drug for IBD, plays a critical role in defining the period of market exclusivity for that drug in Canada. Biosimilar manufacturers seeking to enter the Canadian market with a product referencing the drug covered by CA2827714 would need to navigate this patent.
- Patent Expiry: The expiry date of August 16, 2032, provides a clear timeline for when the patent protection for the claimed invention ends. After this date, the claims of the patent are no longer enforceable, potentially allowing for the introduction of biosimilar versions, assuming other regulatory requirements are met.
- Patent Litigation: Before patent expiry, biosimilar developers often engage in patent litigation to challenge the validity or non-infringement of existing patents. This can lead to early market entry for biosimilars if patents are invalidated or found not to be infringed.
- Regulatory Hurdles: Biosimilar approval in Canada involves demonstrating analytical, clinical, and non-clinical comparability to the reference biologic. The patent landscape is a significant commercial consideration during the development and regulatory submission process for biosimilars.
The specific antibody claimed in CA2827714 would be the target for biosimilar development. If Bristol-Myers Squibb has an approved drug in Canada that falls under the scope of CA2827714, that drug would be the reference biologic.
Key Takeaways
Patent CA2827714, granted to Bristol-Myers Squibb Company, protects pharmaceutical compositions and methods for treating inflammatory bowel disease (IBD) using an antibody or binding region that targets the IL-17 receptor. The patent, filed in August 2012 and expiring in August 2032, is part of a highly competitive landscape for IL-17 pathway inhibitors in IBD treatment. The scope of the patent encompasses compositions and therapeutic uses, while its validity and enforceability are critical for market exclusivity in Canada. The significant market for IBD treatments underscores the commercial importance of such intellectual property.
FAQs
-
What specific antibody is claimed by patent CA2827714?
Patent CA2827714 claims an antibody or an antigen-binding region thereof that specifically binds to an IL-17 receptor. The patent does not name a single specific antibody by its unique identifier in the primary independent claim but rather defines it by its function (binding to the IL-17 receptor). Specific antibodies falling under this definition may be detailed in dependent claims or through biological data presented in the patent.
-
Can a biosimilar competitor enter the Canadian market before August 16, 2032, even with patent CA2827714 in force?
A biosimilar competitor could potentially enter the Canadian market before August 16, 2032, if they successfully challenge the validity of patent CA2827714 through patent litigation, or if the patent is found not to be infringed by their proposed biosimilar product. Regulatory approvals are separate from patent challenges.
-
Does patent CA2827714 protect methods of diagnosing IBD?
No, patent CA2827714 is focused on pharmaceutical compositions and methods of treating inflammatory bowel disease, not on diagnostic methods.
-
What is the geographic scope of patent CA2827714?
The geographic scope of patent CA2827714 is limited to Canada. Protection under this patent is only enforceable within Canadian jurisdiction.
-
Are there any other patents held by Bristol-Myers Squibb related to IL-17 inhibitors for IBD?
It is highly probable that Bristol-Myers Squibb holds other patents related to IL-17 inhibitors for IBD, both in Canada and internationally. Pharmaceutical companies typically build extensive patent portfolios covering different aspects of a drug, including the antibody itself, specific formulations, manufacturing processes, and therapeutic uses. A comprehensive analysis would require searching patent databases for other filings by Bristol-Myers Squibb in this therapeutic area.
Citations
[1] Bristol-Myers Squibb Company. (2017). Canadian Patent CA2827714. Canadian Intellectual Property Office.
